Publish in this journal
Journal Information
Vol. 71. Issue 4.
Pages 305-307 (April 2018)
Scientific letter
DOI: 10.1016/j.rec.2017.12.011
Full text access
Selection of the Best of 2017 in Clinical Arrhythmology
Selección de lo mejor del año 2017 en arritmología clínica
Juan Jiménez-Jáimez
Corresponding author

Corresponding author:
, Rosa Macías Ruiz, Manuel Molina Lerma, Francisco Bermúdez Jiménez, Miguel Álvarez López, Luis Tercedor
Unidad de Arritmias, Hospital Universitario Virgen de las Nieves, Granada, Spain
Related content
Rev Esp Cardiol. 2018;71:303-410.1016/j.rec.2017.12.010
Eva M. Benito, Lluís Mont
Rev Esp Cardiol. 2018;71:304-510.1016/j.rec.2018.01.004
Javier Jiménez-Candil, Ernesto Díaz Infante, José M. Guerra, Nicasio Pérez-Castellano
This item has received
(Daily data update)
Article information
Full Text
Download PDF
Figures (1)
Full Text
To the Editor,

Atrial fibrillation (AF) continues to be the most common arrhythmia, with a prevalence of around 1% to 2% in the general population. In the setting of arrhythmia, it is the leading cause of morbidity and mortality, and the focus of the majority of scientific production. This year has seen the publication of information on the role of direct oral anticoagulants in the prevention of cardioembolic stroke in AF. There have been numerous efficacy and safety studies in clinical practice, most of which are multicenter retrospective studies, but which support the conclusions of previous clinical trials and reinforce the fundamental role of these drugs in the prevention of stroke vs vitamin K antagonists (VKA).1 In addition, the RE-CIRCUIT 2study demonstrated a lower rate of major bleeding when performing AF ablation without interrupting dabigatran therapy compared with conventional treatment with VKA. These findings confirm the safety of interventional cardiology procedures without the suspension of direct oral anticoagulants, as was already the case in clinical practice with VKA. Finally, direct oral anticoagulants have been compared with atrial appendage occlusion, showing that the death and stroke rates are very similar. Nevertheless, these results should be taken with caution and new studies are needed to confirm them.

In the field of syncope, a Spanish group presented the SPAIN3 trial at the Congress of the American College of Cardiology. This trial evaluated the effectiveness of dual-chamber pacing with closed-loop stimulation algorithm for the treatment of vasovagal syncope in patients with recurrent episodes and a cardioinhibitory head-up tilt test (Figure 1). There was a significant reduction in syncope recurrence in patients with a pacemaker with this algorithm compared with patients with a pacemaker in DDI mode, confirming the results of previous studies. Even so, pacing therapy should not be generalized in vasovagal syncope, but reserved only for patients with highly recurrent episodes, significant clinical involvement, and a cardioinhibitory mechanism.


Closed loop stimulation diagram. The sensor detects the change in intracardiac impedance that occurs in the initial phase of vasovagal syndrome and activates sequential stimulation, which prevents bradycardia, decreased sympathetic tone, and hypotension. CLS, closed loop stimulation; LV, left ventricle.


In the field of inherited cardiomyopathies and sudden cardiac death (SCD), an outstanding study is that of the Brussels group on risk stratification of SCD in Brugada syndrome.4 In contrast to previous meta-analyses that only gave importance to syncope in the decision to implant automatic defibrillators in these patients, this group developed a risk scale in which not only the presence of previous syncope or cardiac arrest were significant, but also male sex, spontaneous Brugada pattern type 1 on electrocardiogram, sinus dysfunction, a direct family history of SCD, and inducible ventricular arrhythmias by programmed stimulation. These findings should be confirmed in larger multi-center studies, but will surely keep the debate on this difficult issue alive. In the area of channelopathies, a large randomized study demonstrated the efficacy of flecainide in reducing the arrhythmic burden of catecholaminergic polymorphic ventricular tachycardia.5 This study confirmed flecainide as a therapeutic alternative to beta-blockers, either in monotherapy or in combination, and as an attractive additional therapeutic tool in this disease in addition to beta blockers themselves, sympathectomy, and automatic defibrillator implantation. Finally, a study by a Spanish group was the first to identify mutations in the FLNC gene, which encodes filamin C, as a cause of arrhythmogenic myocardiopathy of the left ventricle.6 This relevant study advances our understanding of the etiopathogenesis of this entity and provides results that are applicable in the clinical setting, because it showed the families described had a high incidence of myocardial fibrosis, ventricular arrhythmias, and SCD. Filamin C is a cytoskeletal anchoring protein previously associated with hypertrophic cardiomyopathy and restrictive cardiomyopathy. However, this new study only included radical mutations, or truncations, establishing a strong phenotype-genotype correlation and confirming the prognostic value of genetic information in SCD risk stratification in these cases of left arrhythmogenic dysplasia.

C.I. Coleman, W.F. Peacock, T.J. Bunz, M.J. Alberts.
Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack.
Stroke, 48 (2017), pp. 2142-2149
H. Calkins, S. Willems, E.P. Gerstenfeld, et al.
Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation.
N Engl J Med., 376 (2017), pp. 1627-1636
G. Barón-Esquivias, C.A. Morillo, A. Moya-Mitjans, et al.
Dual-chamber pacing with closed loop stimulation in recurrent reflex vasovagal syncope. The SPAIN Study.
J Am Coll Cardiol., 70 (2017), pp. 1720-1728
J. Sieira, G. Conte, G. Ciconte, et al.
A score model to predict risk of events in patients with Brugada Syndrome.
Eur Heart J., 38 (2017), pp. 1756-1763
P.J. Kannankeril, J.P. Moore, M. Cerrone, et al.
Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial.
JAMA Cardiol., 2 (2017), pp. 759-766
M.F. Ortiz-Genga, S. Cuenca, M. Dal Ferro, et al.
Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies.
J Am Coll Cardiol., 68 (2016), pp. 2440-2451
Copyright © 2017. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.